Caris Life Sciences, Inc. (CAI) Financial Ratios
23 years of historical data (2003–2025) · Healthcare · Biotechnology
EV/EBITDA
718.40
↓-27% vs avg
5yr avg: 982.30
P/FCF
496.41
↓-26% vs avg
5yr avg: 674.37
P/B Ratio
57.52
↓-26% vs avg
5yr avg: 78.14
30Y Low78.1·High78.1
ROE
↓
-93.2%
↑-109% vs avg
5yr avg: -44.6%
30Y Low-93%·High47%
Debt/EBITDA
↓
0.00
↓-100% vs avg
5yr avg: 3.50
30Y Low0.0·High10.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Caris Life Sciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 496.4x P/FCF, 26% below the 5-year average of 674.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $33.2B | $45.1B | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $32.4B | $44.3B | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -6.17 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 40.89 | 55.55 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 57.52 | 78.14 | — | — | — | — | — | — | — | — | — |
| P/FCF | 496.41 | 674.37 | — | — | — | — | — | — | — | — | — |
| P/OCF | 399.34 | 542.51 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Caris Life Sciences, Inc.'s enterprise value stands at 718.4x EBITDA, 27% below its 5-year average of 982.3x. The Healthcare sector median is 14.9x, placing the stock at a 4723% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 54.57 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | 718.40 | 982.30 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 718.40 | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 662.45 | — | — | — | — | — | — | — | — | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
Caris Life Sciences, Inc. earns an operating margin of 5.6%. Operating margins have expanded from -104.4% to 5.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -93.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 43.4% | 29.2% | 31.0% | 62.6% | 48.1% | 49.4% | 48.6% | 46.7% | 50.4% |
| Operating Margin | 5.6% | 5.6% | -62.4% | -104.4% | -122.2% | 47.3% | 31.3% | 34.4% | 30.3% | 22.4% | 27.3% |
| Net Profit Margin | -66.2% | -66.2% | -68.4% | -111.5% | -124.1% | 9.4% | 7.4% | 18.2% | 20.7% | 2.0% | 10.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.2% | -93.2% | — | — | — | 4.0% | 4.4% | 12.4% | 14.1% | 1.3% | 5.9% |
| ROA | -73.2% | -73.2% | -74.5% | -60.4% | -19.3% | 1.0% | 1.0% | 2.9% | 3.2% | 0.3% | 1.4% |
| ROIC | — | — | — | — | -55.3% | 4.1% | 3.5% | 4.4% | 3.8% | 2.7% | 2.9% |
| ROCE | 7.7% | 7.7% | -103.7% | -71.1% | -22.0% | 5.7% | 5.0% | 6.3% | 5.2% | 3.6% | 4.1% |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Caris Life Sciences, Inc. carries a Debt/EBITDA ratio of 0.0x, which is very conservative (100% below the sector average of 3.0x). The company holds a net cash position — cash of $798M exceeds total debt of $169000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | — | 2.49 | 3.03 | 3.08 | 3.02 | 3.23 | 3.11 |
| Debt / EBITDA | 0.00 | 0.00 | — | — | — | 6.99 | 8.59 | 7.93 | 7.78 | 8.55 | 7.85 |
| Net Debt / Equity | — | -1.38 | — | — | — | 2.41 | 2.96 | 3.01 | 2.96 | 3.13 | — |
| Net Debt / EBITDA | -17.68 | -17.68 | — | — | — | 6.78 | 8.40 | 7.76 | 7.62 | 8.28 | 7.56 |
| Debt / FCF | — | -11.92 | — | — | — | 29.40 | — | — | — | — | — |
| Interest Coverage | — | — | -5.14 | -10.11 | -11.83 | 2.26 | 1.65 | 1.90 | 1.99 | 1.54 | 1.89 |
Net cash position: cash ($798M) exceeds total debt ($169000)
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Caris Life Sciences, Inc.'s current ratio of 7.85x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.55x to 7.85x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.85 | 7.85 | 1.30 | 2.55 | 3.77 | 0.67 | 1.74 | 0.52 | 0.54 | 0.82 | 0.66 |
| Quick Ratio | 7.85 | 7.85 | 1.06 | 2.04 | 3.43 | 0.67 | 1.74 | 0.52 | 0.54 | 0.82 | 0.66 |
| Cash Ratio | 6.29 | 6.29 | 0.40 | 1.28 | 2.99 | 0.41 | 0.16 | 0.29 | 0.25 | 0.40 | 0.34 |
| Asset Turnover | — | 0.72 | 1.20 | 0.74 | 0.36 | 0.11 | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 |
| Inventory Turnover | — | — | 5.90 | 4.43 | 3.80 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 50.41 | 78.13 | 65.93 | 56.80 | 179.14 | 139.92 | 145.22 | 105.46 | 103.79 | 111.75 |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Caris Life Sciences, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | 63.8% | 28.5% | 4.1% | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.2% | 0.1% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $1.7B | $255M | $255M | $255M | $18M | $18M | $20M | $20M | $19M | $21M |
Peer Comparison
Compare CAI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CAIYou | $33B | -6.2 | 718.4 | 496.4 | — | 5.6% | -93.2% | — | 0.0 |
 VCYT | $3B | 44.2 | 44.2 | 22.7 | 70.1% | 11.2% | 5.3% | 4.4% | 0.7 |
 ADPT | $3B | -15.2 | — | — | 59.7% | -90.8% | -62.5% | -41.6% | — |
 NAUT | $331M | -5.6 | — | — | — | — | -32.3% | — | — |
 CDIO | $141M | -0.6 | — | — | 100.0% | -23977.9% | -134.0% | -222.7% | — |
 SEER | $103M | -1.3 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 IMDX | $95M | -1.2 | — | — | 39.3% | -3245.1% | -1480.7% | — | — |
 ASBP | $63M | -5.1 | — | — | — | — | — | — | — |
 YDES | $35M | -15.1 | — | — | 30.4% | -286.5% | -42.7% | -63.3% | — |
 AIMD | $7M | -1.0 | — | — | -153.7% | -66772.2% | -74.4% | -39.8% | — |
 VRAX | $2M | -0.1 | — | — | -838.2% | -97344.8% | -114.4% | -273.2% | — |
| Healthcare Median | — | 23.2 | 14.9 | 19.0 | 65.8% | -6.4% | -36.7% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
See CAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CAI vs VCYT
See how CAI stacks up against sector leader Veracyte, Inc..
Start ComparisonFrequently Asked Questions
What is Caris Life Sciences, Inc.'s P/E ratio?
Caris Life Sciences, Inc.'s current P/E ratio is -6.2x. This places it at the 50th percentile of its historical range.
What is Caris Life Sciences, Inc.'s EV/EBITDA?
Caris Life Sciences, Inc.'s current EV/EBITDA is 718.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Caris Life Sciences, Inc.'s ROE?
Caris Life Sciences, Inc.'s return on equity (ROE) is -93.2%. The historical average is 7.4%.
Is CAI stock overvalued?
Based on historical data, Caris Life Sciences, Inc. is trading at a P/E of -6.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Caris Life Sciences, Inc.'s profit margins?
Caris Life Sciences, Inc. has 5.6% operating margin.
How much debt does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.